

Luca C Gobbi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2664250/publications.pdf>

Version: 2024-02-01

11
papers

396
citations

1163117

8
h-index

1281871

11
g-index

13
all docs

13
docs citations

13
times ranked

610
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of High Brain-Penetrant and Reversible Monoacylglycerol Lipase PET Tracers for Neuroimaging. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2191-2207.	6.4	7
2	Discovery, synthesis and evaluation of novel reversible monoacylglycerol lipase radioligands bearing a morpholine-3-one scaffold. <i>Nuclear Medicine and Biology</i> , 2022, 108-109, 24-32.	0.6	6
3	The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17656-17689.	6.4	28
4	A Comparative Study of in vitro Assays for Predicting the Nonspecific Binding of PET Imaging Agents in vivo. <i>ChemMedChem</i> , 2020, 15, 585-592.	3.2	8
5	Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10287-10306.	6.4	25
6	Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11165-11181.	6.4	19
7	Characterization of 3 Novel Tau Radiopharmaceuticals, ¹¹ C-RO-963, ¹¹ C-RO-643, and ¹⁸ F-RO-948, in Healthy Controls and in Alzheimer Subjects. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1869-1876.	5.0	81
8	Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7350-7370.	6.4	74
9	Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4266-4277.	6.4	55
10	Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 79, 27-35.	4.0	25
11	Radioligand development for molecular imaging of the central nervous system with positron emission tomography. <i>Drug Discovery Today</i> , 2014, 19, 1936-1944.	6.4	67